Clinical Trial Update: Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updates empagliflozin for heart failure with preserved ejection fraction and microvascular dysfunction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Microvascular Dysfunction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction | Phase 4 | Status: UNKNOWN